enzastaurin has been researched along with Cancer of Lung in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 17 (73.91) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Hannun, YA; Sadeghi, MM; Salama, MF | 1 |
| Bhattacharya, A; Köberle, M; Koczan, D; Kottek, T; Kunz, M; Magin, TM; Saalbach, A; Schönherr, M; Siebolts, U; Simon, JC; Szymczak, S; Wickenhauser, C | 1 |
| Cao, FF; Meng, FL; Wang, Y; Zhang, LL; Zhang, Y; Zhong, DS; Zhou, QH | 1 |
| Fong, T; Jurasz, P; Lesyk, G; Ruvolo, PP | 1 |
| Ciardiello, F; Gridelli, C; Laus, G; Martinelli, E; Morgillo, F; Pepe, S; Troiani, T | 1 |
| Giovannetti, E; Graff, JR; Peters, GJ; Sigmond, J; Smid, K; Tekle, C | 1 |
| Giaccone, G; Giovannetti, E; Hanauske, AR; Honeywell, R; Kuenen, B; Peters, GJ; Sigmond, J; Tekle, C | 1 |
| Kim, KW; Lu, B; Moretti, L; Niermann, KJ; Quarles, CC; Tawtawy, MN; Tu, T; Willey, CD; Xiao, D | 1 |
| Barata, F; Barlesi, F; Bearz, A; Bepler, G; Chiappori, A; Chouaki, N; Iscoe, N; Liepa, AM; Park, K; Reck, M; Scagliotti, G; Soria, JC; von Pawel, J; Wagle, A; Zhao, YD | 1 |
| Bepler, G; Chen, T; Hofmann, J; Lee, SH; Zhou, J | 1 |
| Baldwin, JR; Koshiji, M; Kunitoh, H; Murakami, H; Nakamura, Y; Nokihara, H; Ohe, Y; Shukuya, T; Takahashi, T; Tamura, T; Tanai, C; Yamamoto, N | 1 |
| Allgayer, H; Körner, A; Manegold, C; Mudduluru, G | 1 |
| Bradford, D; Bufill, J; Casey, EM; Fisher, W; Hanna, N; Harb, W; Latz, JE; Li, X; Nattam, S; Patel, J; Wu, J | 1 |
| Asmar, L; Barrera, D; Bromund, J; Choksi, JK; Couch, LS; Jotte, R; Kocs, DM; Obasaju, CK; Patt, DA; Peng, G; Periman, PO; Pritchard, S; Raju, RN; Rousey, SR; Schlossberg, HR; Socinski, MA; Stinchcombe, T; Treat, J; Wang, Y; Weissman, CH | 1 |
| Chouaki, N; Eschbach, C; Kennedy, L; Ramlau, R; Reck, M; San Antonio, B; Szczesna, A; Vansteenkiste, J; Visseren-Grul, C; von Pawel, J | 1 |
| Gemma, A; Kitamura, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Noro, R; Okano, T; Seike, M; Shimokawa, T; Soeno, C; Uesaka, H; Yoshimura, A | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Abel, E; Ciuleanu, T; Fløtten, Ø; Grønberg, BH; Hahka-Kemppinen, M; Knuuttila, A; Krejcy, K; Langer, SW; Liepa, AM; Munoz, M; Sundstrøm, S | 1 |
| Alexandrow, MG; Altiok, S; Bepler, G; Chen, J; Gray, JE; Schell, MJ; Tai, DF; Walsh, FW | 1 |
| Herbst, RS; Lahn, M; Oh, Y; Wagle, A | 1 |
| Fields, AP; Murray, NR | 1 |
| Bepler, G; Burris, H; Cleverly, A; Herbst, RS; Lahn, M; Musib, L; Oh, Y | 1 |
4 review(s) available for enzastaurin and Cancer of Lung
| Article | Year |
|---|---|
Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Prognosis; Protein Isoforms; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras) | 2021 |
The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Indoles; Lung Neoplasms; Phosphorothioate Oligonucleotides; Protein Kinase C; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Survival Rate | 2015 |
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Pemetrexed | 2010 |
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors | 2007 |
9 trial(s) available for enzastaurin and Cancer of Lung
| Article | Year |
|---|---|
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Female; Folic Acid; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Salvage Therapy; Survival Rate; Vitamin B 12 | 2010 |
A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Pemetrexed; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life | 2010 |
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Placebos | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Quality of Life; Treatment Outcome | 2012 |
Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.
Topics: Aged; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Precancerous Conditions; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Risk; Smoking | 2013 |
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Immunoenzyme Techniques; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Salvage Therapy; Survival Rate | 2008 |
10 other study(ies) available for enzastaurin and Cancer of Lung
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.
Topics: Animals; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Induction; Gene Expression Regulation, Neoplastic; Genomic Library; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Proteins; Nevus, Pigmented; Oligonucleotide Array Sequence Analysis; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Kinases; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Skin Neoplasms; Transduction, Genetic; Tumor Stem Cell Assay; Up-Regulation | 2014 |
The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.
Topics: Antineoplastic Agents; Apoptosis; Blood Platelets; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indoles; Lung Neoplasms; Platelet Aggregation; Protein Kinase C beta; Protein Kinase Inhibitors; Secretory Vesicles; Time Factors; Vascular Endothelial Growth Factor A | 2015 |
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Intracellular Space; Lung Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Signal Transduction | 2008 |
Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Drug Synergism; Folic Acid Antagonists; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Pemetrexed; Phosphorylation; Polymerase Chain Reaction; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2008 |
Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Endothelium, Vascular; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Phosphorylation; Polymorphism, Single Nucleotide; Protein Kinase C; Protein Kinase C beta; Signal Transduction; Small Cell Lung Carcinoma | 2010 |
Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Gene Knockdown Techniques; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleic Acid Hybridization; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Indoles; Janus Kinase 1; Lung Neoplasms; MAP Kinase Signaling System; MicroRNAs; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2012 |
Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Humans; Indoles; Isoenzymes; K562 Cells; Lung Neoplasms; Mice; Neoplasms; Oncogenes; Protein Kinase C; Rats; Signal Transduction | 2008 |